ARQT - Company ID 0001787306
The table below shows Arcutis Biotherapeutics, Inc.'s cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q1 2025 | Q1 2024 | Q1 2023 | Q1 2022 | Q1 2021 |
|---|---|---|---|---|---|---|
| Operating cash flow | $2.24M | -$30.38M | -$31.60M | -$80.34M | -$56.98M | -$46.20M |
| Capital expenditure | $0.00 | $608.00K | $0.00 | $82.00K | $124.00K | $554.00K |
| Investing cash flow | -$11.33M | $11.75M | -$28.70M | $107.75M | $15.30M | $62.00M |
| Dividends paid | - | - | - | - |
Arcutis Biotherapeutics, Inc. reported operating cash flow of -$5.63M for fiscal year 2025. That is up 95.0% from -$112.16M in fiscal 2024. Over the 8 fiscal years shown, operating cash flow grew from -$14.09M (FY 2018) to -$5.63M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | $1.07M | $395.00K | $161.76M | $100.00K | $14.72M | $207.81M |